TWD 65.7
(0.15%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 929.61 Million TWD | -15.28% |
2022 | 1.09 Billion TWD | 6.37% |
2021 | 1.03 Billion TWD | -3.79% |
2020 | 1.07 Billion TWD | -0.95% |
2019 | 1.08 Billion TWD | 34.96% |
2018 | 802.16 Million TWD | 53.44% |
2017 | 522.78 Million TWD | -0.92% |
2016 | 527.64 Million TWD | -37.28% |
2015 | 841.2 Million TWD | 2.74% |
2014 | 818.78 Million TWD | 34.37% |
2013 | 609.35 Million TWD | 46.72% |
2012 | 415.32 Million TWD | -27.59% |
2011 | 573.59 Million TWD | -7.89% |
2010 | 622.75 Million TWD | 7.13% |
2009 | 581.33 Million TWD | 449.19% |
2008 | 105.85 Million TWD | 0.0% |
2006 | 633.67 Million TWD | -11.61% |
2005 | 716.93 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 342.43 Million TWD | 19.84% |
2024 Q1 | 285.75 Million TWD | 1.13% |
2023 Q4 | 282.56 Million TWD | -20.24% |
2023 FY | 929.61 Million TWD | -15.28% |
2023 Q1 | 244.73 Million TWD | 105.73% |
2023 Q2 | 297.83 Million TWD | 21.69% |
2023 Q3 | 354.25 Million TWD | 18.95% |
2022 Q3 | 300.14 Million TWD | -20.45% |
2022 FY | 1.09 Billion TWD | 6.37% |
2022 Q1 | 300.84 Million TWD | 11.38% |
2022 Q2 | 377.29 Million TWD | 25.41% |
2022 Q4 | 118.96 Million TWD | -60.37% |
2021 Q2 | 248.92 Million TWD | 21.33% |
2021 Q3 | 249.62 Million TWD | 0.28% |
2021 FY | 1.03 Billion TWD | -3.79% |
2021 Q4 | 270.11 Million TWD | 8.21% |
2021 Q1 | 205.16 Million TWD | -7.07% |
2020 Q2 | 215.7 Million TWD | -26.17% |
2020 Q4 | 220.76 Million TWD | -5.93% |
2020 Q3 | 234.69 Million TWD | 8.8% |
2020 Q1 | 292.14 Million TWD | 10.43% |
2020 FY | 1.07 Billion TWD | -0.95% |
2019 Q2 | 243.16 Million TWD | 29.33% |
2019 Q4 | 264.54 Million TWD | 34.85% |
2019 FY | 1.08 Billion TWD | 34.96% |
2019 Q1 | 188.01 Million TWD | 4.68% |
2019 Q3 | 196.17 Million TWD | -19.32% |
2018 Q2 | 185.6 Million TWD | -12.4% |
2018 FY | 802.16 Million TWD | 53.44% |
2018 Q3 | 225.07 Million TWD | 21.27% |
2018 Q1 | 211.88 Million TWD | 117.44% |
2018 Q4 | 179.6 Million TWD | -20.2% |
2017 Q1 | 187.04 Million TWD | 57.43% |
2017 Q2 | 119.86 Million TWD | -35.91% |
2017 Q4 | 97.44 Million TWD | -17.73% |
2017 FY | 522.78 Million TWD | -0.92% |
2017 Q3 | 118.43 Million TWD | -1.19% |
2016 Q1 | 157.12 Million TWD | -40.42% |
2016 Q4 | 118.8 Million TWD | 12.29% |
2016 Q3 | 105.8 Million TWD | -27.48% |
2016 FY | 527.64 Million TWD | -37.28% |
2016 Q2 | 145.9 Million TWD | -7.14% |
2015 FY | 841.2 Million TWD | 2.74% |
2015 Q1 | 176.99 Million TWD | -20.99% |
2015 Q2 | 204.78 Million TWD | 15.7% |
2015 Q3 | 195.69 Million TWD | -4.44% |
2015 Q4 | 263.73 Million TWD | 34.77% |
2014 Q3 | 193.85 Million TWD | -12.08% |
2014 Q2 | 220.5 Million TWD | 22.21% |
2014 FY | 818.78 Million TWD | 34.37% |
2014 Q4 | 224 Million TWD | 15.55% |
2014 Q1 | 180.42 Million TWD | -17.98% |
2013 FY | 609.35 Million TWD | 46.72% |
2013 Q1 | 144.77 Million TWD | 108.78% |
2013 Q3 | 112.34 Million TWD | -15.06% |
2013 Q2 | 132.26 Million TWD | -8.65% |
2013 Q4 | 219.97 Million TWD | 95.8% |
2012 Q2 | 167.43 Million TWD | 40.44% |
2012 FY | 415.32 Million TWD | -27.59% |
2012 Q1 | 119.21 Million TWD | -21.22% |
2012 Q4 | 69.34 Million TWD | 20.53% |
2012 Q3 | 57.53 Million TWD | -65.64% |
2011 Q3 | 115.88 Million TWD | -63.12% |
2011 Q2 | 314.24 Million TWD | 4093.94% |
2011 Q1 | -7.86 Million TWD | -101.26% |
2011 FY | 573.59 Million TWD | -7.89% |
2011 Q4 | 151.33 Million TWD | 30.59% |
2010 Q2 | - TWD | 0.0% |
2010 FY | 622.75 Million TWD | 7.13% |
2010 Q4 | 622.75 Million TWD | 0.0% |
2010 Q1 | - TWD | 0.0% |
2010 Q3 | - TWD | 0.0% |
2009 FY | 581.33 Million TWD | 449.19% |
2008 FY | 105.85 Million TWD | 0.0% |
2006 FY | 633.67 Million TWD | -11.61% |
2005 FY | 716.93 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Grape King Bio Ltd | 2.49 Billion TWD | 62.766% |
Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | 26.195% |
Maywufa Company Ltd. | 211.01 Million TWD | -340.535% |
ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | -195.593% |
Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 81.04% |
LIWANLI Innovation Co., Ltd. | - TWD | -Infinity% |
PhytoHealth Corporation | -121.67 Million TWD | 864.001% |
SCI Pharmtech, Inc. | 160.3 Million TWD | -479.921% |
Formosa Laboratories, Inc. | 674.97 Million TWD | -37.726% |
PharmaEssentia Corporation | - TWD | -Infinity% |
Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 82.29% |